Metabolic Compound

Retatrutide

The 'Godzilla' of weight loss; a triple-hormone agonist for unprecedented fat loss and metabolic health.

Scientific Overview

Retatrutide is an investigational triple agonist developed by Eli Lilly. It mimics GLP-1, GIP, and glucagon, leading to significant improvements in weight, glycemic control, and liver health.

Key Research Benefits

✓Unrivaled weight loss (up to 24%+)
✓Reverses liver fat (80%+ reduction)
✓Normalizes blood sugar
✓Reduces visceral fat

Potential Side Effects

⚠Nausea

⚠Diarrhea

⚠Vomiting

⚠Increased heart rate (mild)

Research Protocols

Common Dosages

Triple Agonist protocol

1 mg -> 12 mg

Weekly

“Newest generations of metabolic therapy”

Note: Dosages listed are common research protocols found in peer-reviewed literature and clinical trials. Individual results and requirements may vary significantly in a research context.

Dose Calculator

🧮 Peptide Reconstitution Calculator

Vial Quantity (mg)

Total amount of peptide in the vial.

Bacteriostatic Water Added (mL)

Volume of water used to mix.

Desired Dosage (mcg)

mcg

Draw to this mark

10 Units

or 0.10 mL on a U-100 syringe

Concentration:2.50 mg/mL

Peptide per Unit:25.00 mcg/unit

*Always double-check your calculations. This tool is for educational purposes only.

Explore Retatrutide

Quick Explainer

“Retatrutide is the next generation of weight loss peptides. As a triple-hormone-receptor agonist, it targets GLP-1, GIP, and glucagon receptors simultaneously, making it potentially the most powerful metabolic tool ever discovered.”

Stack Retatrutide with…

Curated stacking partners researched alongside Retatrutide. Each link opens a dedicated stack page with combined benefits, side-effect overlap, and half-life considerations.

Performance stack
Retatrutide + Ipamorelin
Gentle GH releaser that amps muscle growth and fat loss without the harsh sides.

Retatrutide by goal

Read Retatrutide's profile filtered through specific research goals.

Retatrutide for Fat Loss Retatrutide for Recovery

Molecular Profile

linear

Modified Peptide

39 AA Sequence

Quick Reference

Status: Research Compound
Category: Metabolic
Common Dosage: 1 mg -> 12 mg; Weekly
Plasma decay: t½ 6.0 d · ~3% remaining at 30 d

Strictly for research purposes. Not for human consumption.

Related tools

Medical Disclaimer

Information provided on DoseVault is for educational and research purposes only. This website does not advocate for the human use of peptides. Peptides are currently sold as research chemicals and are not FDA-approved for human consumption. Always consult a licensed medical professional before considering any protocol.